ArticleHippokratia
Mean standardized uptake value (SUVmean) and global hepatic glycolysis as potential imaging markers reflecting hepatic functional capacity: evidence from 18F-FDG PET/CT.
Article in Hippokratia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Hepatic superscan on [Abdominal radiology (New York) · 2026Pooled it
- Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study.International journal of medical sciences · 2021Trial
- A streamlined predictive model for predicting the risk of recurrence after liver transplantation for hepatocellular carcinoma was constructed based on preoperativeFrontiers in oncology · 2026Article
- [18F]-FDG PET-CT in Malignant Melanoma.Diagnostics (Basel, Switzerland) · 2025Article
- Baseline [European journal of nuclear medicine and molecular imaging · 2024Article
- Predicting the Recurrence of Hepatocellular Carcinoma after Primary Living Donor Liver Transplantation Using Metabolic Parameters Obtained fromJournal of clinical medicine · 2022Article
- Differences among [Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatic cirrhosis caused by hepatic steatosis and hepatitis is irreversible. Early and non-invasive diagnosis of these diffuse hepatopathies calls for possible imaging markers. The purpose of this study was to explore the changes in global hepatic glucose metabolism following hepatic steatosis, hepatitis, or cirrhosis on
methodsA total of 178 subjects (51 healthy controls, 41 patients with hepatic steatosis, 50 patients with chronic hepatitis, and 36 patients with hepatic cirrhosis) were recruited, and their hepatic
resultsStatistical differences were observed in SUV
conclusionsSUV
Indexed as
Identifiers
31695300PMC6825420W2995315777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.